Skip to main content
OpenTrials
Completed

NCT Number: NCT03880266

A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

The objective of this study is to assess the efficacy and safety of glycopyrronium cloth, 2.4% when used to treat palmar hyperhidrosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

9 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

California Dermatology & Clinical Research Institute, Encinitas, California, United States

Loading trial locations.

About this study

This is a pilot study assessing the safety and efficacy of glycopyrronium cloth in patients with palmar hyperhidrosis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent and assent (for subjects under legal adult age).
  • Age ≥9 years.
  • Primary palmar hyperhidrosis for at least 6 months duration.
  • Average sweat severity score of ≥4 at Baseline.
  • Hyperhidrosis Disease Severity Scale of 3 or 4 at Baseline.
  • Willing to comply with the protocol. Subjects under legal adult age will be assessed by the investigator as to their ability to comply with the protocol.
  • Male or non-pregnant (negative urine pregnancy test in female subjects of child-bearing potential), non-lactating females.

Exclusion criteria

  • Subjects who have taken or are currently taking glycopyrronium cloth, 2.4%.
  • Prior surgical procedure for hyperhidrosis.
  • Iontophoresis for the palms within 4 weeks of Baseline.
  • Treatment with botulinum toxin (e.g., Botox®) for palmar hyperhidrosis within 1 year of Baseline.
  • Open wounds or inflammatory lesions on the hands or, any condition that may alter the barrier function of the skin on the hands.
  • Secondary palmar hyperhidrosis or presence of a condition that may cause secondary hyperhidrosis (e.g., lymphoma, malaria, severe anxiety not controlled by medication, carcinoid syndrome, substance abuse, hyperthyroidism).
  • Known history of Sjögren's syndrome or Sicca syndrome.
  • History of glaucoma, inflammatory bowel disease, toxic megacolon, active febrile illness, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis or myasthenia gravis.
  • Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy.

Treatment and study plan

Glycopyrronium cloth, 2.4%

Drug

Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium

Vehicle

Drug

Pre-saturated 100% polypropylene, nonwoven, fabric cloth

Primary outcomes

  1. Mean Change From Baseline to Week 2 in Hand Sweating Severity Score

    Time frame: Baseline, Week 2

    The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis [score on a scale from 0 (better) -10 (worse)].

Secondary outcomes

  1. Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2

    Time frame: Baseline, Week 2

    Hyperhidrosis Disease Severity Scale (HDSS) is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.

    1 (better), 2, 3, 4 (worse)

  2. Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 2

    Time frame: Baseline, Week 2

    Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; average of the change in the gravimetric measurement of sweat produced at baseline compared with Week 2

  3. Mean Percent Change From Baseline in Gravimetrically-measured Sweat Production at Week 2

    Time frame: Baseline, Week 2

    Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; calculation of percentage difference in sweat production at week 2 compared to baseline sweat production

  4. Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically-measured Sweat Production From Baseline at Week 2

    Time frame: Baseline, Week 2

    Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; confidence interval represents difference between vehicle and active group

Sponsors and collaborators

Lead sponsor

Journey Medical Corporation

Industry

Registry information

Official study title

A Phase 2, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 19, 2019
Registry last updated
Aug 25, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.